Published in PLoS One on November 29, 2013
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Modulation of K(Ca)3.1 channels by eicosanoids, omega-3 fatty acids, and molecular determinants. PLoS One (2014) 0.79
The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke. J Cereb Blood Flow Metab (2015) 0.78
NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. Cell Commun Signal (2014) 0.77
Protein transduction therapy into cochleae via the round window niche in guinea pigs. Mol Ther Methods Clin Dev (2016) 0.75
Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Mol Pharmacol (2017) 0.75
Potassium Channels in Regulation of Vascular Smooth Muscle Contraction and Growth. Adv Pharmacol (2016) 0.75
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A (2000) 4.01
The functional network of ion channels in T lymphocytes. Immunol Rev (2009) 3.21
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov (2009) 3.12
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem (2000) 2.85
Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. Circ Res (2006) 2.22
Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem (1997) 1.99
Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol (2008) 1.98
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation (2009) 1.86
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood (2008) 1.61
Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell (2005) 1.58
Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers. Cardiovasc Res (2010) 1.57
Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol (2010) 1.56
Kv1.3 channels as a potential target for immunomodulation of CD4+ CD28null T cells in patients with acute coronary syndrome. Clin Immunol (2011) 1.53
The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation (2006) 1.53
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev (2008) 1.52
Allograft vasculopathy versus atherosclerosis. Circ Res (2006) 1.50
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A (2009) 1.44
Vascular remodeling in transplant vasculopathy. Circ Res (2007) 1.42
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol (2007) 1.41
Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis. Arterioscler Thromb (1991) 1.30
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A (2010) 1.29
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther (2012) 1.19
Orai1, a critical component of store-operated Ca2+ entry, is functionally associated with Na+/Ca2+ exchanger and plasma membrane Ca2+ pump in proliferating human arterial myocytes. Am J Physiol Cell Physiol (2009) 1.17
Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. Am J Pathol (1998) 1.10
Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol (2003) 1.09
Ras/MEK/ERK Up-regulation of the fibroblast KCa channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-beta suppression of myogenesis. J Biol Chem (2000) 1.09
The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab (2011) 1.08
Characterization of ion channels involved in the proliferative response of femoral artery smooth muscle cells. Arterioscler Thromb Vasc Biol (2010) 1.03
Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant (2011) 1.03
Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc (2009) 1.02
NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br J Pharmacol (2013) 0.96
Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778. Transplantation (2008) 0.95
Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy (2006) 0.94
Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One (2012) 0.94
The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem (2013) 0.93
The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts. Clin Transplant (1994) 0.88
Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol (2012) 0.88
Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts. Am J Pathol (2002) 0.87
Potassium channels and proliferation of vascular smooth muscle cells. Circ Res (2005) 0.87
Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation (1997) 0.85
Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. Transplantation (2012) 0.82
Successful heterotopic heart transplantation in rat. Microsurgery (1994) 0.78
The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. Transplantation (2013) 0.78
The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. Transplantation (2004) 0.77
KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol (2010) 0.77
Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation (2003) 0.76
Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med (2006) 3.39
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev (2005) 2.39
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
Improving the efficiency of advanced life support training: a randomized, controlled trial. Ann Intern Med (2012) 2.24
Right atrial mass after primary repair of an atrial septal defect: thrombus masquerading as a myxoma. Ann Thorac Surg (2007) 2.23
Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation (2008) 2.22
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev (2003) 2.05
Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res (2012) 2.02
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation (2009) 1.86
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82
KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int (2008) 1.80
Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart. Transplantation (2009) 1.73
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon (2011) 1.59
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol (2008) 1.58
Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation (2009) 1.54
Management and outcome of cats with ureteral calculi: 153 cases (1984-2002). J Am Vet Med Assoc (2005) 1.47
In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev (2008) 1.46
Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci (2011) 1.46
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A (2009) 1.44
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol (2007) 1.41
Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proc Natl Acad Sci U S A (2008) 1.38
Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem (2010) 1.37
Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant (2010) 1.36
Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation (2006) 1.35
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol (2004) 1.31
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A (2010) 1.29
Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets (2010) 1.29
A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem (2003) 1.22
Outcome of permanent tracheostomy for treatment of upper airway obstruction in cats: 21 cases (1990-2007). J Am Vet Med Assoc (2009) 1.12
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J (2005) 1.11
The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab (2011) 1.08
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol (2009) 1.08
Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart. Circ Res (2012) 1.06
Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol (2012) 1.05
The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol Biol Cell (2009) 1.03
Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet (2002) 1.01
LAD-ligation: a murine model of myocardial infarction. J Vis Exp (2009) 0.98
The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Biochem J (2004) 0.98
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Dev Res (2011) 0.98
Whole Genome Sequencing of Thermus oshimai JL-2 and Thermus thermophilus JL-18, Incomplete Denitrifiers from the United States Great Basin. Genome Announc (2013) 0.97
Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778. Transplantation (2008) 0.95
Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue. Stem Cells Dev (2013) 0.95
Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem (2001) 0.94
Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One (2012) 0.94
AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology (2007) 0.94
The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem (2013) 0.93
Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem (2004) 0.93
Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins. FASEB J (2008) 0.93
Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Curr Med Chem (2004) 0.92
Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels. Mol Pharmacol (2011) 0.92
Antegrade pyelography for suspected ureteral obstruction in cats: 11 cases (1995-2001). J Am Vet Med Assoc (2003) 0.92
Techniques for experimental heterotopic and orthotopic tracheal transplantations - When to use which model? Transpl Immunol (2007) 0.92
Long-term outcome of cats treated conservatively or surgically for peritoneopericardial diaphragmatic hernia: 66 cases (1987-2002). J Am Vet Med Assoc (2004) 0.91
Thermus oshimai JL-2 and T. thermophilus JL-18 genome analysis illuminates pathways for carbon, nitrogen, and sulfur cycling. Stand Genomic Sci (2013) 0.89
Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol (2010) 0.89
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem (2014) 0.89
Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One (2013) 0.89
Imaging in-stent restenosis: an inexpensive, reliable, and rapid preclinical model. J Vis Exp (2009) 0.89
Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. Int J Alzheimers Dis (2012) 0.89
Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol (2012) 0.88
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem (2006) 0.88
Identification of the V genes encoding xenoantibodies in non-immunosuppressed rhesus monkeys. Immunology (2005) 0.87
Similarities in the immunoglobulin response and VH gene usage in rhesus monkeys and humans exposed to porcine hepatocytes. BMC Immunol (2006) 0.86
Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS One (2011) 0.86
Surgical management of adrenal gland tumors with and without associated tumor thrombi in dogs: 40 cases (1994-2001). J Am Vet Med Assoc (2003) 0.86
Sustained inhibition of epsilon protein kinase C inhibits vascular restenosis after balloon injury and stenting. Circulation (2010) 0.86
Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Mol Pharmacol (2005) 0.86
Clinical, clinicopathologic, radiographic, and ultrasonographic abnormalities in cats with ureteral calculi: 163 cases (1984-2002). J Am Vet Med Assoc (2005) 0.86
Evaluation of ameroid ring constrictors for treatment for single extrahepatic portosystemic shunts in dogs: 168 cases (1995-2001). J Am Vet Med Assoc (2005) 0.86
Introducing the first polymer-free leflunomide eluting stent. Atherosclerosis (2008) 0.86
Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respir Res (2014) 0.86
Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new κ-KTX subfamily. Biochem Pharmacol (2012) 0.86
Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. Br J Pharmacol (2013) 0.85
SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts. Cardiovasc Res (2012) 0.85
Does microglial dysfunction play a role in autism and Rett syndrome? Neuron Glia Biol (2012) 0.84
K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. PLoS One (2013) 0.84
Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3. PLoS One (2013) 0.84
Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells. J Cell Sci (2011) 0.84
Bioluminescence imaging for assessment of immune responses following implantation of engineered heart tissue (EHT). J Vis Exp (2011) 0.83
Small animal models of experimental obliterative bronchiolitis. Am J Respir Cell Mol Biol (2013) 0.83
Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. Transplantation (2012) 0.82
Nanomolar bifenthrin alters synchronous Ca2+ oscillations and cortical neuron development independent of sodium channel activity. Mol Pharmacol (2014) 0.82
The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opin Ther Targets (2013) 0.82
Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium. J Heart Lung Transplant (2009) 0.81
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem (2008) 0.81
Assessment of physiologic natural killer cell cytotoxicity in vitro. Hum Immunol (2011) 0.81
Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation (2008) 0.81
Outcome after renal transplantation in 26 dogs. Vet Surg (2012) 0.81
A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection. Transplantation (2009) 0.80
Human leukocyte antigen I knockdown human embryonic stem cells induce host ignorance and achieve prolonged xenogeneic survival. Circulation (2011) 0.80
Heterotopic and orthotopic tracheal transplantation in mice used as models to study the development of obliterative airway disease. J Vis Exp (2010) 0.80
Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. Am J Vet Res (2003) 0.80
Human internal mammary artery (IMA) transplantation and stenting: a human model to study the development of in-stent restenosis. J Vis Exp (2012) 0.80